Abec L Required information: ABEC L Composition: Each film-coated tablet contains IP equivalent to abacavir's sulfate, equivalent to 600 mg of Abacair and 1000 mg of lamivudine. Indications: Treatment of HIV-1 with other antiretroviral drugs. Type 1 Dosage: Recommended Oral Dose for ABEC-L is designed for adults with one of the tablet PCs each day with other antiretroviral drugs. ABEC - L can be with or without food. Adverse reactions: severe, and sometimes even fatal to this product ingredients have a sensitive reaction with abacavir sulfate (abacavir), the ABEC resolution of the component, insomnia, depression, headache, migraine, fatigue / fatigue, dizziness / halo Dizziness, nausea, diarrhea, rash, fever, abdominal pain / gastritis, abnormal dreams and anxiety are common side effects. Warnings and Precautions: Do not at the same time with other abacavir and / or lamivudine products. Serious, and sometimes even fatal to this product ingredients are sensitive to ABEC-L and other abacavir products. The patient's high risk of carrying the HLA-B * 5701 allele has a sensitive response to this product ingredient, abacavir. Before the start of abacavir (abacavir) therapy, the screening of the HLA-B * 5701 allele is recommended; it is found that this method can reduce this risk and produce a sensitive response to this product ingredient. Screening is also recommended before recovery, abacavir (abacavir) status of patients unknown HLA-B * 5701 previously tolerated abacavir (abacavir). Treatment with ABEC-L should be suspended in any patient to develop clinical or laboratory data indicative of lactate hypoglycemia (186%), loss of water (37%) or severe hepatotoxicity. Patients receiving interferon alfa with or without triazole nucleoside indium, ABEC-L should be closely monitored for its toxicity with treatment, especially liver decompensation. Termination of ABEC-L should be considered medically acceptable. Because ABEC-L is a combination of fixed doses, patients who do not prescribe creatinine clearance rates <50 ml / min Drug interactions: ethanol can reduce the secretion of abacavir (abacavir), resulting in increased overall exposure. Taking lamivudine and zalcitabine can inhibit each other in the intracellular parasite (enos). Therefore, the use of ABEC-L combined with zalcitabine is not recommended. Pregnancy: Class C of Drugs: ABEC-L should be used during pregnancy only at potential benefits beyond risk. Breastfeeding mothers: mothers should not breastfeed their children to avoid the risk of HIV infection after childbirth. Contraindications: The patient has previously exhibited a product of abacavir (abacavir) or any other component. Will never be restarted by ABEC-L or any other product contained in abacavir (abacavir) after a sensitive reaction to this product ingredient, abacavir, regardless of HLA-B * 5701. The patient's liver is deficient. Storage: Store in a cool dry place. Presentation: 30 pieces of container. For more information, please refer to the complete information on the regulations.